8-KRegulation FDExhibits & Filings

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Sep 3, 2026)

Filed September 3, 2026For Securities:ABBV

Summary

AbbVie Inc. (ABBV) announced on September 3, 2026, the successful completion of its acquisition of Apogee Therapeutics, Inc. This strategic move signifies AbbVie's commitment to expanding its pipeline and potential future revenue streams through targeted acquisitions. Investors should focus on the implications of this acquisition for AbbVie's long-term growth prospects, particularly concerning the integration of Apogee's assets and their contribution to the company's future earnings. The company also provided forward-looking statements regarding its 2026 full-year and third-quarter adjusted diluted EPS guidance, hinting at the expected financial impact of this acquisition. While the full details of the financial statements and exhibits are incorporated by reference, the core message is the completion of a significant strategic transaction aimed at bolstering AbbVie's therapeutic portfolio.

Key Highlights

  • 1AbbVie Inc. has completed the acquisition of Apogee Therapeutics, Inc.
  • 2The acquisition is expected to enhance AbbVie's pipeline and future growth potential.
  • 3AbbVie has provided updated financial guidance for its 2026 full-year and third-quarter adjusted diluted EPS.
  • 4The company anticipates benefits from the integration of Apogee's operations, employees, and pipeline.
  • 5Key Apogee pipeline assets, including zumilokibart (APG777) and APG273, are highlighted for their potential.
  • 6The filing includes forward-looking statements about the acquisition's impact on earnings and R&D progress.
  • 7AbbVie cautions that actual results may differ materially due to various risks and uncertainties.

Frequently Asked Questions

This 8-K filing announces the completion of AbbVie's acquisition of Apogee Therapeutics, Inc. and incorporates by reference the related press release. It also includes forward-looking statements about the expected financial impact and strategic benefits of this acquisition.

The filing specifically mentions zumilokibart (APG777) and APG273 as key pipeline assets from Apogee Therapeutics that AbbVie is acquiring. These are expected to contribute to AbbVie's future development and commercial opportunities.

AbbVie has provided guidance for its 2026 full-year and third-quarter adjusted diluted EPS, suggesting an expected positive impact from the Apogee acquisition. However, the company also warns of potential risks and uncertainties that could affect actual results.

AbbVie has identified several risks, including the possibility that anticipated benefits and synergies may not be realized, integration challenges, the risk that acquired R&D assets may not achieve expected success or regulatory approval, unknown liabilities, intellectual property challenges, competition, and difficulties in the R&D process.